Table 4.
Fulvestrant 500 mg (n = 362) | Fulvestrant 250 mg (n = 374) | |
---|---|---|
Response rate (%) | 45.6 | 39.6 |
Mean DoCBa in months (SE) | 21.6 (1.3) | 18.3 (1.1) |
Expected DoCB (months) | 9.8 | 7.2 |
Ratio of expected DoCB (95 % CI)b | 1.36 (1.07–1.73) | |
P value | 0.013 |
CI confidence interval, DoCB duration of clinical benefit, SE standard error
aLimited to patients with clinical benefit, i.e. a subset of all randomized patients
bRatios of >1 favor fulvestrant 500 mg